Everest Medicines Limited (1952.HK)

24.600 +1.100 (+4.68%) As of 11:18AM HKT. Market open.

Everest Medicines Limited

CITIC Pacific Plaza
16th Floor 1168 West Nanjing Road Jing’an District
Shanghai 200041
China

https://www.everestmedicines.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 432

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Wei Fu	Executive Chairman	N/A	N/A	1983
Mr. Yongqing Luo	CEO & Executive Director	11.89M	N/A	1970
Mr. Ian Ying Woo	CFO, President & Executive Director	12.27M	N/A	1973
Dr. Jason M. Brown Ph.D.	Chief Business Officer	N/A	N/A	1973
Dr. Wei Yang Ph.D.	Chief Scientific Officer	N/A	N/A	1970
Mr. Rico Liang	Chief Product Officer	N/A	N/A	1969
Ms. Sandra Zeng	Chief Medical Officer	N/A	N/A	N/A
Ms. Yee Wa Lau	Joint Company Secretary	N/A	N/A	1974
Ms. Leah Liu	Joint Company Secretary & VP of Corporate Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Everest Medicines Limited, a biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company also provides Zetomipzomib, a immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.

Corporate governance

Everest Medicines Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.